



TITLE: Preparation of N-heterocyclyl amides and sulfonamides  
 as p38 kinase inhibitors  
 INVENTOR(S): Dugar, Sundeep; McEnroe, Glen  
 PATENT ASSIGNEE(S): Scios Inc., USA  
 SOURCE: PCT Int. Appl., 195 pp.  
 CODEN: PIXDZ2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005033072	A2	20050414	WO 2004-US32403	20040930 <--
WO 2005033072	A3	20060112		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2540828	A1	20050414	CA 2004-2540828	20040930 <--
EP 1675830	A2	20060705	EP 2004-789449	20040930 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007507529	T	20070329	JP 2006-534154	20040930 <--
US 2006199821	A1	20060907	US 2005-196650	20050803 <--
PRIORITY APPLN. INFO.:			US 2003-507633P	P 20030930 <--
			US 2004-957504	A1 20040930
			WO 2004-US32403	W 20040930

OTHER SOURCE(S): CASREACT 142:392427; MARPAT 142:392427

GI



AB The title compds. I [R1 = alkyl, cycloalkyl, heterocycloalkyl, aryl; L = CO,  
 SO2; X = O, CO, (un)substituted CH2, NH; n = 0-3; R2 = H, alkyl, aryl, etc.; Y  
 = (un)substituted NH2, OH; one of Z1 and Z2 = CH, and the other is either CH  
 or N], useful for inhibiting p38 kinase, were prepared. E.g., a multi-step  
 synthesis of (IS)-II, starting from 4-amino-2-chloropyridine and 2-naphthoyl  
 chloride, was given. The compds. I were tested against p38 $\alpha$  kinase in the

diluted whole blood assay (biol. data were given for representative compds. I). The pharmaceutical composition comprising the compound I is disclosed.  
IT 849745-68-2P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of N-heterocyclyl amides and sulfonamides as p38 kinase inhibitors)  
RN 849745-68-2 ZCPLUS  
CN 1H-Indole-3-acetamide, N-[(4-fluorophenyl)methyl]-1-methyl- $\alpha$ -oxo-N-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl- (CA INDEX NAME)

Absolute stereochemistry.

